top
Search terms
Results 1 - 6 of 6 - ordered by :
Eurointervention

[...]182 patients (116 females, 83±6 years; mean STS score 11.0±9.5) were divided into three groups according to the antithrombotic therapy. The rate of stroke or bleeding (≥ major in Valve ...

Date : 06/05/2016 Item size : 31336 bytes
Ehjournal

Abstract Aims To assess the incidence and timing of atrial fibrillation (AF), describe antithrombotic therapy use, and evaluate the association of AF with 90 day mortality and other secondary ...

European Heart Journal, Lopes, Renato D., Elliott, Laine E., White, Harvey D., Hochman, Judith S., Van de Werf, Frans, Ardissino, Diego, Nielsen, Torsten T., Weaver, W. Douglas, Widimsky, Petr, ...

Date : 01/08/2009
Ehjournal

Abstract Aims To assess the incidence and timing of atrial fibrillation (AF), describe antithrombotic therapy use, and evaluate the association of AF with 90 day mortality and other secondary ...

European Heart Journal, Lopes, Renato D., Elliott, Laine E., White, Harvey D., Hochman, Judith S., Van de Werf, Frans, Ardissino, Diego, Nielsen, Torsten T., Weaver, W. Douglas, Widimsky, Petr, ...

Date : 01/08/2009 Item size : 288607 bytes
Escardio

Csilla CELENG (Budapest, Hungary) 09:12 6605 Outcomes of acute coronary syndromes with non-obstructive coronary artery disease: insights from the Alberta COAPT registry Kevin BAINEY (Edmonton, ...

Risk factors and comorbidities: effects on clinical outcome in coronary artery disease

Date : 31/08/2016 Item size : 76205 bytes
ESC365

Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Date : 28/08/2016